Achillion Pharmaceuticals Inc. (Nasdaq: ACHN) reported additional upbeat preliminary data from a Phase 1b study of its hepatitis C treatment ACH-1625. But the stock price dropped 34 cents to close at $3.05.
Achillion Reports Upbeat Data
January 11, 2010 at 15:59 PM EST
